Bausch Health Companies Inc. Impairment of Intangible Assets (Excluding Goodwill)
Bausch Health Companies Inc. (BHC) reported Impairment of Intangible Assets (Excluding Goodwill) of $14.00 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2020-05-07
- Bausch Health Companies Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2020-03-31 was $14.00M, a 366.67% increase year-over-year.
- Bausch Health Companies Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-12-31 was $20.00M.
- Bausch Health Companies Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-09-30 was $25.00M, a 38.89% increase year-over-year.
- Bausch Health Companies Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2019-06-30 was $10.00M, a 96.54% decline year-over-year.
- Bausch Health Companies Inc. impairment of intangible assets (excluding goodwill) for fiscal 2019 was $58.00M.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2020-03-31 | $14.00M 10-Q · filed 2020-05-07 | $34.00M derived: sum of 2 quarters · filed 2020-05-07 | $59.00M derived: sum of 3 quarters · filed 2020-05-07 | $69.00M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $45.00M derived: sum of 2 quarters · filed 2020-02-19 | $55.00M derived: sum of 3 quarters · filed 2020-02-19 | $58.00M 10-K · filed 2020-02-19 |
| 2019-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $35.00M derived: sum of 2 quarters · filed 2019-11-04 | $38.00M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $13.00M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $3.00M 10-Q · filed 2019-05-06 | |||
| 2018-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $307.00M derived: sum of 2 quarters · filed 2019-11-04 | $341.00M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $289.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $323.00M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $34.00M 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |